Considerable progress has been made in the past several years in the scientific
understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement …

Half a century ago, the common occurrence of relapses in patients with acute myeloid
leukemia (AML) after achieving a morphologic remission, together with the inverse linear …

Multiparameter flow cytometry (MFC)-based MRD testing is increasingly utilized in AML, but
methodologies and assay characteristics vary substantially [1–3]. Nonetheless, following …

Measurable residual disease (MRD) by multiparametric flow cytometry (MFC) before
allogeneic hematopoietic cell transplantation (HCT) identifies patients at high risk of acute …

Reduced intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning regimens
have expanded use of allogeneic hematopoietic cell transplantation (HCT) in AML to include …

The multikinase inhibitor sorafenib improves event-free survival (EFS) when used with 7+ 3
in adults with newly-diagnosed acute myeloid leukemia (AML), irrespective of the FLT3 …

Racial and socioeconomic disparities impact outcomes after chemotherapy and limit access
to allogeneic hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML), yet …

Allogeneic hematopoietic cell transplantation (HCT) remains an important curative-intent
treatment for many patients with acute myeloid leukemia (AML), but AML recurrence after …

Outcomes of adults with AML after allografting vary widely. While numerous covariates have
been associated with relapse, non-relapse mortality (NRM), and/or shorter survival, the …

Measurable residual disease (MRD) is a strong but imprecise predictor of relapse in acute
myeloid leukemia. Many patients fall into the outlier categories of MRD positivity without …